Used in research and development for Alzheimer’s disease, this antibody targets BACE1 (beta-secretase 1), an enzyme involved in the production of amyloid-beta peptides. By inhibiting BACE1 activity, it helps reduce amyloid plaque formation, a hallmark of Alzheimer’s pathology. It serves as a reference tool in assays evaluating BACE1 inhibition, supporting the screening and validation of potential therapeutic agents. Frequently employed in preclinical studies, it aids in understanding target engagement and mechanism of action for new drug candidates. Its high specificity makes it valuable in immunohistochemistry, Western blotting, and ELISA applications within neuroscience research.